Tags

Type your tag names separated by a space and hit enter

New progestogens in oral contraceptives.
Am J Obstet Gynecol. 1987 Oct; 157(4 Pt 2):1059-63.AJ

Abstract

The aim of using new synthetic progestogens (gestodene and norgestimate) in oral hormonal contraceptives is to find a combination that has a more beneficial effect on metabolism and endometrium than presently available formulations. Our studies with low-dose pills containing 30 micrograms ethinyl estradiol/150 micrograms levonorgestrel or 30 micrograms ethinyl estradiol/150 micrograms desogestrel compared with the new pills with 35 micrograms ethinyl estradiol/250 micrograms norgestimate or 30 micrograms ethinyl estradiol/75 micrograms gestodene revealed no significant alterations of serum glucose after glucose loading. With all four combination pills, insulin levels were slightly elevated when compared with controls. Studies of the lipid metabolism showed that depending on the type and estrogen combination, progestogens have different effects on lipid metabolism. The new progestogens seem to have a more pronounced effect on triglycerides, whereas total cholesterol and high-density lipoprotein cholesterol remain almost unchanged. In general, it could be shown that low-dose oral contraceptives have little impact on lipid metabolism. Studies with low-dose monophasic preparations, including the new formulations, reveal only a low effect on blood coagulation. According to our and other data on the new progestogens in oral contraceptives available so far, it can be expected that such low-dose monophasic and triphasic combination pills will be beneficial during longtime use with respect to side effects on the cardiovascular system and control of the menstrual cycle.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Heidelberg, West Germany.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2960242

Citation

Runnebaum, B, and T Rabe. "New Progestogens in Oral Contraceptives." American Journal of Obstetrics and Gynecology, vol. 157, no. 4 Pt 2, 1987, pp. 1059-63.
Runnebaum B, Rabe T. New progestogens in oral contraceptives. Am J Obstet Gynecol. 1987;157(4 Pt 2):1059-63.
Runnebaum, B., & Rabe, T. (1987). New progestogens in oral contraceptives. American Journal of Obstetrics and Gynecology, 157(4 Pt 2), 1059-63.
Runnebaum B, Rabe T. New Progestogens in Oral Contraceptives. Am J Obstet Gynecol. 1987;157(4 Pt 2):1059-63. PubMed PMID: 2960242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New progestogens in oral contraceptives. AU - Runnebaum,B, AU - Rabe,T, PY - 1987/10/1/pubmed PY - 1987/10/1/medline PY - 1987/10/1/entrez KW - Biology KW - Blood Coagulation Effects KW - Blood Pressure KW - Carbohydrate Metabolic Effects KW - Cardiovascular Effects KW - Contraception--side effects KW - Contraceptive Agents, Estrogen--side effects KW - Contraceptive Agents, Female--side effects KW - Contraceptive Agents, Progestin--side effects KW - Contraceptive Agents--side effects KW - Contraceptive Methods--side effects KW - Diseases KW - Endometrium KW - Ethinyl Estradiol--side effects KW - Family Planning KW - Genitalia KW - Genitalia, Female KW - Glucose Metabolism Effects KW - Levonorgestrel--side effects KW - Lipid Metabolic Effects KW - Lipids KW - Literature Review KW - Metabolic Effects KW - Oral Contraceptives, Combined--side effects KW - Oral Contraceptives, Low-dose--side effects KW - Oral Contraceptives, Phasic--side effects KW - Oral Contraceptives--side effects KW - Physiology KW - Urogenital System KW - Uterus SP - 1059 EP - 63 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 157 IS - 4 Pt 2 N2 - The aim of using new synthetic progestogens (gestodene and norgestimate) in oral hormonal contraceptives is to find a combination that has a more beneficial effect on metabolism and endometrium than presently available formulations. Our studies with low-dose pills containing 30 micrograms ethinyl estradiol/150 micrograms levonorgestrel or 30 micrograms ethinyl estradiol/150 micrograms desogestrel compared with the new pills with 35 micrograms ethinyl estradiol/250 micrograms norgestimate or 30 micrograms ethinyl estradiol/75 micrograms gestodene revealed no significant alterations of serum glucose after glucose loading. With all four combination pills, insulin levels were slightly elevated when compared with controls. Studies of the lipid metabolism showed that depending on the type and estrogen combination, progestogens have different effects on lipid metabolism. The new progestogens seem to have a more pronounced effect on triglycerides, whereas total cholesterol and high-density lipoprotein cholesterol remain almost unchanged. In general, it could be shown that low-dose oral contraceptives have little impact on lipid metabolism. Studies with low-dose monophasic preparations, including the new formulations, reveal only a low effect on blood coagulation. According to our and other data on the new progestogens in oral contraceptives available so far, it can be expected that such low-dose monophasic and triphasic combination pills will be beneficial during longtime use with respect to side effects on the cardiovascular system and control of the menstrual cycle. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/2960242/New_progestogens_in_oral_contraceptives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(87)80132-1 DB - PRIME DP - Unbound Medicine ER -